A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in Hepatic Impairment Patients and Healthy Volunteers

NCT01146938 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Essential Hypertension
Hepatic Impairment

Interventions

DRUG: fimasartan
DRUG: fimasartan

Sponsor

Boryung Pharmaceutical Co., Ltd

Collaborators

[object Object]
[object Object]